

INFORMATION DISCLOSURE STATEMENT	Application #	10/528,833
	Confirmation #	3759
	Filing Date	03/25/2005
	First Inventor	DURANTEL
	Art Unit	
	Examiner	
	Docket #	P08599US00/BAS

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

S I R :

This IDS is submitted pursuant to 37 CFR. §1.97-1.98 and includes the following:

- ☒ A **listing** of the references on PTO-1449.
- ☒ A copy of all **non-US** references which are listed on the PTO-1449 (US refs not required).
- ☐ A copy of a corresponding foreign **Search Report** which explains the relevance of the references noted therein.
- ☐ A separate **explanation of relevance**.

Please note the following particulars concerning the filing of this IDS:

- ☒ 1. This IDS is filed at whichever is the latest of:
 - within three months of the filing date of a NATIONAL APPLICATION other than a CPA, or
 - within three months of the date of entry into the NATIONAL STAGE as set forth in 37 CFR. §1.491 in an international application, or
 - before the mailing date of a first Office Action on the merits or after filing of an RCE (*but if a first Office Action is mailed but not yet received and the date on the face of the attached foreign communication makes it evident that this IDS is submitted within three months from the mailing of the search report, then applicant is entitled to have this IDS considered under 2.B. below and such boxes should be considered as having been checked*).
- ☐ 2. This IDS is filed **after a first Office Action**, but before a Final Action, Allowance, or any other action which closes prosecution, **and**:
 - ☐ A. Is accompanied by a payment in the amount of \$180.00 required by 37 CFR. §1.17(p).

or

 - ☐ B. I hereby state that each item of information contained in this IDS was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this IDS.
 - ☐ C. I hereby state that no item of information in this IDS herewith was cited in a communication from a foreign patent office in a counterpart foreign application, and, to my knowledge after making reasonable inquiry, was known to any individual designated in 37 CFR. §1.56(c) more than 3 months prior to the filing of this IDS.
 - ☐ D. An appropriate Statement is attached.

- ☐ 3. This IDS is filed **after** a final action or allowance, but on/before payment of the issue fee, and:
- ☐ A. is accompanied by a payment in the amount of \$180.00 required by 37 CFR. §1.17(p).
- and
- ☐ B. I hereby state that each item of information contained in this IDS was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this IDS.
- ☐ C. I hereby state that no item of information in this IDS herewith was cited in a communication from a foreign patent office in a counterpart foreign application, and, to my knowledge after making reasonable inquiry, was known to any individual designated in 37 CFR. §1.56(c) more than 3 months prior to the filing of this IDS.
- ☐ D. An appropriate Statement is attached.
- ☐ 4. This IDS does not comply with 37 CFR 1.97-1.98, and is being filed **for placement in the file** pursuant to 37 CFR. §1.97(i). .
- ☒ 5. It will also be appreciated that:
- a. It is believed that this IDS complies fully with 37 CFR 1.56 and 1.97-98 and with MPEP § 609; but if for some reason it does not and will not be entered, the examiner is requested to telephone the undersigned so that any deficiency can be timely remedied.
- b. Some of the documents may have markings thereon, but no significance should be attached to those markings.
- c. These documents are not necessarily analogous art.
- d. Where an English language translation of an abstract is provided from a public source, applicant cannot vouch for the accuracy of that translation.
- ☒ 6. If no payment is enclosed and a fee is due in connection with this communication or if the payment enclosed is insufficient, the Commissioner is authorized to charge any fee or additional fee due with this communication to Deposit Account No. 12-0555.

Respectfully submitted,



By: B. Aaron Schulman
Registration No.: 31,877

Date: June 16, 2006

STITES & HARBISON PLLC ♦ 1199 North Fairfax St. ♦ Suite 900 ♦ Alexandria, VA 22314
TEL: 703-739-4900 ♦ FAX: 703-739-9577 ♦ CUSTOMER NO. 00881

Substitute for Form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT	Application #	10/528,833
	Confirmation #	3759
	Filing Date	03/25/2005
	First Inventor	DURANTEL
	Art Unit	
	Examiner	
Sheet 1 of 2	Docket #	P08599US00/BAS

U.S. PATENT DOCUMENTS				
Exam. Initial*	Document No. Number - Kind	Publ. Date MM-DD-YYYY	Name Patentee or Applicant	Relevance Passages/Figs.
	US-			
	US-			

FOREIGN PATENT DOCUMENTS					
Exam. Initial*	Country-Number-Kind	Publ. Date MM-DD-YYYY	Name Patentee or Applicant	Relevance Passages/Figs.	Translation

NON PATENT LITERATURE DOCUMENTS		
Exam. Initial*	Include NAME of the author (in CAPS), Title of Article/Item, Date, Page(s), Volume-Issue No., Publisher, City and/or Country where published	Translation
	WANG ET AL, "Novel Mechanism for Reverse Transcription in Hepatitis B Viruses" Nov. 1993, ppgs. 6507-6512; vol. 67 – no. 11, Journal of Virology	
	BOCK ET AL, "Selection of Hepatitis B Virus Polymerase Mutants With Enhanced Replication by Lamivudine Treatment After Liver Transplantation" Feb. 2002, ppgs. 264-273, vol.122 – no. 2; Gastroenterology	
	GUNTHER ET AL, "A Novel Method for Efficient Amplification of Whole Hepatitis B Virus Genomes Permits Rapid Functional Analysis and Reveals Deletion Mutants in Immunosuppressed Patients" Sept. 1995, ppgs. 5437-5444, vol. 69 – no. 9, Journal of Virology	
	ALLEN ET AL, "Identification and Characterization of Mutations in Hepatitis B Virus Resistant to Lamivudine" June 1998, ppgs. 1670-1677, vol. 27 – no. 6; Hepatology	
	PICHOUD ET AL, "Transient Selection of a Hepatitis B Virus Polymerase Gene Mutant Associated With a Decreased Replication Capacity and Famciclovir Resistance" Jan. 1999, ppgs. 230-237, vol. 29 – no. 1, Hepatology	
	SEEGER ET AL, "Hepatitis B Virus Biology" March 2000; ppgs. 51-68; vol. 64 – no. 1; Microbiology and Molecular Biology Reviews	
	GUNTHER ET AL, "A Novel Method for Efficient Amplification of Whole Hepatitis B Virus Genomes Permits Rapid Functional Analysis and Reveals Deletion Mutants in Immunosuppressed Patients" Sept. 1995, ppgs. 5437-5444; vol. 69 – no. 9, Journal of Virology	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

* Examiner: Initial if considered, whether or not citation is in conformance with MPEP §609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to the applicant.

Substitute for Form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT	Application #	10/528,833
	Confirmation #	3759
	Filing Date	03/25/2005
	First Inventor	DURANTEL
	Art Unit	
	Examiner	
Sheet <u>2</u> of <u>2</u>	Docket #	P08599US00/BAS

U.S. PATENT DOCUMENTS				
Exam. Initial*	Document No. Number - Kind	Publ. Date MM-DD-YYYY	Name Patentee or Applicant	Relevance Passages/Figs.
	US-			
	US-			
	US-			

FOREIGN PATENT DOCUMENTS					
Exam. Initial*	Country-Number-Kind	Publ. Date MM-DD-YYYY	Name Patentee or Applicant	Relevance Passages/Figs.	Translation

NON PATENT LITERATURE DOCUMENTS		
Exam. Initial*	Include NAME of the author (in CAPS), Title of Article/Item, Date, Page(s), Volume-Issue No., Publisher, City and/or Country where published	Translation
	SEIGNERES ET AL, "Duck hepatitis B virus polymerase gene mutants associated with resistance to lamivudine have a decreased replication capacity in vitro and in vivo" 2001, ppgs. 114-122, Journal of Hepatology	
	KRAMVIS, "The core promoter of hepatitis B virus" 1999, ppgs. 415-427, Journal of Viral Hepatitis	
	SEIGNERES ET AL, "Evolution of Hepatitis B Virus Polymerase Gene Sequence during Famciclovir Therapy for Chronic Hepatitis B", 2000, ppgs. 1221-1233, Journal of Infectious Diseases	
	SEIGNERES ET AL, "Inhibitory Activity of Dioxolane Purine Analogs on Wild-Type and Lamivudine-Resistant Mutants of Hepadnaviruses" 2002, ppgs. 710-722, vol. 36 - no.3, Hepatology	
	NORDER ET AL, "Complete Genomes, Phylogenetic Relatedness, and Structural Proteins of Six Strains of the Hepatitis B Virus, Four of Which Represent Two New Genotypes" 1994, ppgs. 489-503, Virology	
	The Hepatitis B Virus Page " www.globalseve.net/~harlequin/HBV/hbvcycle.htm " Printout.	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

* Examiner: Initial if considered, whether or not citation is in conformance with MPEP §609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to the applicant.